602 related articles for article (PubMed ID: 31018667)
41. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
[TBL] [Abstract][Full Text] [Related]
42. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
[TBL] [Abstract][Full Text] [Related]
43. Impact of the
Hu X; Liu C; Zhang M; Zhang W
Pharmacogenomics; 2022 Jul; 23(11):639-648. PubMed ID: 35880550
[No Abstract] [Full Text] [Related]
44. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
45. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
Hochholzer W; Valina CM; Bömicke T; Amann M; Stratz C; Nührenberg T; Trenk D; Neumann FJ
Thromb Haemost; 2015 Jul; 114(1):109-14. PubMed ID: 25832119
[TBL] [Abstract][Full Text] [Related]
46. Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Nishikawa M; Takeda Y; Isomura N; Tanigawa T; Nanasato M; Tsukahara K; Kimura K; Takayama T; Hirayama A; Kato M; Nishikawa H; Nishimura Y; Isshiki T; Yokoi H;
J Atheroscler Thromb; 2020 Jan; 27(1):13-24. PubMed ID: 31092743
[TBL] [Abstract][Full Text] [Related]
47.
Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
[TBL] [Abstract][Full Text] [Related]
48. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
49. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
50. Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
Bianco M; Gravinese C; Cerrato E; Nuñez-Gil I; Destefanis P; Luciano A; Biscaglia S; Quadri G; Tizzani E; Corleto A; Giolitto S; Lo Savio L; Campo G; Varbella F; Pozzi R
Minerva Cardioangiol; 2019 Apr; 67(2):94-101. PubMed ID: 30895761
[TBL] [Abstract][Full Text] [Related]
51. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Peng W; Shi X; Xu X; Lin Y
Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
[TBL] [Abstract][Full Text] [Related]
52. Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Kang J; Park KW; Lee H; Hwang D; Yang HM; Rha SW; Bae JW; Lee NH; Hur SH; Han JK; Shin ES; Koo BK; Kim HS
Circulation; 2023 Jan; 147(2):108-117. PubMed ID: 36342475
[TBL] [Abstract][Full Text] [Related]
53. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
[TBL] [Abstract][Full Text] [Related]
54. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
[TBL] [Abstract][Full Text] [Related]
55. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
[TBL] [Abstract][Full Text] [Related]
56. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Wu H; Qian J; Sun A; Wang Q; Ge J
Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
[TBL] [Abstract][Full Text] [Related]
57. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
[TBL] [Abstract][Full Text] [Related]
58. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
[TBL] [Abstract][Full Text] [Related]
59. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM; Al-Allawi NAS
J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
[TBL] [Abstract][Full Text] [Related]
60. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
